35.61
Newamsterdam Pharma Company Nv Aktie (NAMS) Neueste Nachrichten
Price-Driven Insight from (NAMS) for Rule-Based Strategy - news.stocktradersdaily.com
It is Poised to be a Bull Market for NewAmsterdam Pharma Company NV (NAMS) - Setenews
SCYNEXIS (NASDAQ:SCYX) versus NewAmsterdam Pharma (NASDAQ:NAMS) Head to Head Analysis - Defense World
NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by Affinity Asset Advisors LLC - Defense World
NewAmsterdam Pharma’s REMBRANDT Trial: A Potential Game-Changer in Cardiovascular Treatment - MSN
NewAmsterdam Pharma Co (NAMS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
NAMS Analyst Forecasts - Quiver Quantitative
NewAmsterdam Pharma Company Grants Inducement Share Options to New Hires - Quiver Quantitative
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Saturn V Capital Management LP Buys 104,342 Shares of NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock gain from lower inflationMarket Growth Review & Free Technical Pattern Based Buy Signals - Newser
Is NewAmsterdam Pharma Company N.V. (KH6) stock attractive post correction2025 Volatility Report & Weekly High Conviction Trade Ideas - Newser
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock see PE expansionJuly 2025 Macro Moves & Entry and Exit Point Strategies - Newser
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap DownHere's Why - MarketBeat
NAMS: PREVAIL CVOT remains on track for 2026, with regulatory and commercial momentum building - TradingView
JPMorgan Chase & Co. Increases Stock Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
How NewAmsterdam Pharma Company N.V. (KH6) stock trades after earningsWeekly Trade Analysis & Consistent Profit Trade Alerts - Newser
Transcript : NewAmsterdam Pharma Company N.V. Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 03 - marketscreener.com
A better buy-in window may exist right now for NewAmsterdam Pharma Company NV (NAMS) - Setenews
Goldman Sachs Maintains NewAmsterdam Pharma Company N.V. (NAMS) Neutral Recommendation - MSN
Is NewAmsterdam Pharma Company N.V. (KH6) stock a defensive play amid uncertaintyEarnings Summary Report & Reliable Intraday Trade Alerts - Newser
Will NewAmsterdam Pharma Company N.V. stock benefit from commodity pricesGap Down & Smart Money Movement Alerts - Newser
Owner Bain Capital Life Sciences Fund II LP Files To Sell 267,429 Of NewAmsterdam Pharma Co NV [NAMS] - TradingView
Owner BCLS II Investco LP Files To Sell 4,500,000 Of NewAmsterdam Pharma Co NV [NAMS] - TradingView
Will NewAmsterdam Pharma Company N.V. (KH6) stock announce special dividendWeekly Earnings Recap & Technical Entry and Exit Alerts - Newser
Is NewAmsterdam Pharma Company N.V. Equity Warrant stock a dividend growth opportunity2025 Risk Factors & AI Forecasted Entry and Exit Points - Newser
Why NewAmsterdam Pharma Company N.V. (KH6) stock signals breakout potential2025 Stock Rankings & Low Drawdown Momentum Ideas - Newser
Franklin Resources Inc. Purchases 78,300 Shares of NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
(NAMS) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Can NewAmsterdam Pharma Company N.V. Equity Warrant stock outperform in 2025 bull marketPortfolio Gains Report & Technical Buy Zone Confirmation - BỘ NỘI VỤ
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December - Sahm
NewAmsterdam Pharma (NASDAQ:NAMS) Sets New 12-Month HighHere's Why - MarketBeat
NewAmsterdam Pharma stock hits all-time high at 41.56 USD - Investing.com India
NewAmsterdam Pharma stock hits all-time high at 41.56 USD By Investing.com - Investing.com Australia
Handelsbanken Fonder AB Boosts Holdings in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Discipline and Rules-Based Execution in NAMSW Response - news.stocktradersdaily.com
What drives NewAmsterdam Pharma Company NV KH6 stock priceDebt-to-Equity Ratio Analysis & Get Ahead with Our Profit-Packed Picks - earlytimes.in
Bank of New York Mellon Corp Acquires New Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Is NewAmsterdam Pharma Company N.V. Equity Warrant stock a top pick in earnings seasonSwing Trade & Safe Investment Capital Preservation Plans - newser.com
Can a trend reversal in NewAmsterdam Pharma Company N.V. Equity Warrant lead to recovery - newser.com
Technical analysis overview for NewAmsterdam Pharma Company N.V. Equity Warrant stockMarket Movers & Risk Controlled Stock Alerts - newser.com
Is NewAmsterdam Pharma Company N.V. stock a good choice for value investorsQuarterly Risk Review & Weekly Market Pulse Alerts - newser.com
Will NewAmsterdam Pharma Company N.V. stock maintain dividend yield - newser.com
Is NewAmsterdam Pharma Company N.V. (KH6) stock a fit for income portfoliosOil Prices & Long-Term Growth Stock Strategies - newser.com
How NewAmsterdam Pharma Company N.V. stock performs in high volatility marketsPortfolio Gains Report & Safe Entry Zone Identification - newser.com
What does recent volatility data suggest for NewAmsterdam Pharma Company N.V. Equity WarrantPortfolio Growth Summary & Technical Buy Zone Confirmation - newser.com
How NewAmsterdam Pharma Company N.V. (KH6) stock compares with tech leaders2025 Momentum Check & Risk Adjusted Swing Trade Ideas - newser.com
Visual analytics tools that track NewAmsterdam Pharma Company N.V. Equity Warrant performanceIndex Update & Weekly High Momentum Picks - newser.com
How NewAmsterdam Pharma Company N.V. Equity Warrant stock performs in stagflation2025 Biggest Moves & AI Forecast for Swing Trade Picks - newser.com
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock recover faster than marketJuly 2025 Patterns & Weekly Top Gainers Trade List - newser.com
(NAMS) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Can NewAmsterdam Pharma Company N.V. Equity Warrant stock withstand economic slowdownJuly 2025 Action & Precise Swing Trade Entry Alerts - newser.com
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):